生物技术公司Moderna, Inc. (MRNA) 今日盘后股价大幅下跌8.37%，引起了市场的高度关注。
消息面上，Moderna披露其研发中的季节性流感疫苗mRNA-1010收到了美国食品药品监督管理局（FDA）的拒收函。监管机构认为该公司提交的申请材料存在不完整之处，尚不符合受理标准，这一监管挫折打击了投资者对其疫苗管线进展的信心。
生物技术公司Moderna, Inc. (MRNA) 今日盘后股价大幅下跌8.37%，引起了市场的高度关注。
消息面上，Moderna披露其研发中的季节性流感疫苗mRNA-1010收到了美国食品药品监督管理局（FDA）的拒收函。监管机构认为该公司提交的申请材料存在不完整之处，尚不符合受理标准，这一监管挫折打击了投资者对其疫苗管线进展的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.